Exact Sciences Stock - analyst views and business model snapshot

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 14:05 UTC. Details in the imprint.

Exact Sciences (US30063P1057) develops molecular diagnostic tests for early cancer detection and prevention. With no new market-moving filings or major press releases today from the company or leading newswires, the focus shifts to its longer-term strategy and business positioning.

What recent filings show

Exact Sciences last reported quarterly results for the first quarter of 2026 in late April, posting continued double-digit revenue growth driven by its core screening portfolio, according to its most recent quarterly update. Investor relations materials

The company has also maintained a steady cadence of clinical development and regulatory updates across its pipeline, with management repeatedly emphasizing a long-term goal of expanding its testing menu across multiple cancer types.

Analyst consensus and valuation snapshot

On the sell-side, the stock carries a mixed analyst view, with a MarketBeat consensus rating around "Reduce" and an average price target near $92, implying downside from recent trading levels. MarketBeat data

That stance reflects a balancing act between solid top-line growth and continued losses as the company invests heavily in R&D and commercialization, leaving valuation metrics such as the P/E ratio not meaningful on a trailing basis.

How the company makes money

Exact Sciences generates most of its revenue from diagnostic testing services, led by its flagship Cologuard stool DNA test for colorectal cancer screening, along with additional oncology assays that support earlier detection and treatment guidance for a range of malignancies.

Where the stock trades today

Exact Sciences stock (US30063P1057) trades on Nasdaq under the ticker EXAS; the latest verified quote data point was above $100 per share in recent sessions, based on public market data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.